COUNSELING REGARDING PREGNANCY- RELATED DRUG EXPOSURES BY FAMILY PHYSICIANS IN ONTARIO
Main Article Content
Keywords
Family physicians, counseling, information, drugs, pregnancy
Abstract
Background
Family physicians may play a significant role in providing information to their patients on the effects of medication exposure during pregnancy. Women must receive accurate information, as unrealistic perception of teratogenic risk may lead to inadequate treatment of maternal disease or termination of otherwise wanted pregnancies.
Objectives
To collect data on the current practices of family physicians in providing information regarding pregnancy-related drug exposures, in particular, their confidence in providing counseling and their sources of information.
Methods
A mailed survey was sent to a random sample of family physicians in Ontario. Outcome measures included the proportion of family physicians that feel confident in providing counseling regarding drugs in pregnancy, most common resources, barriers to counseling and preferences for future educational programs.
Results
Of the 756 surveys, 400 (53%) were returned, 265 (66%) by practicing physicians caring for women of childbearing age. Most (80.3%) felt confident in providing counseling, though a majority (56%) stated that available sources of information are not adequate. The most commonly consulted source was the Motherisk Program (62%). Lack of evidence-based information was cited as the major barrier.
Conclusions
Although family physicians were confident in providing counseling to pregnant patients with regards to drug use, more than one-half thought that the available sources of information are not adequate. The dissemination of more evidence-based information in this field is needed.
References
2. Van Trigt AM, Waardenburg CM, Haaijer- Ruskamp FM, de Jong-van Berg LTW. Questions about drugs: how do pregnant women solve them? Pharm World Sci 1994;16:254-9.
3. Henry A, Crowther C. Sources of advice on medication use in pregnancy and reasons for medication uptake and cessation during pregnancy. Aust NZJ Obstet Gynaecol 2000;40:173-5.
4. Koren G, Bologa M, Long D, Feldman Y, Shear NH. Perception of teratogenic risk by pregnant women exposed to drugs and chemicals during the first trimester. Am J Obstet Gynecol 1989;160:1190-4.
5. Uhl K, Kennedy DL, Kweder SL. Information on Medication Use in Pregnancy. Am Fam Physician 2003;67: 2476, 2478.
6. Perlman SE, Postlewaite D, Stump S, Bielan B, Jantzi RS. Taking a sexual history from and counselling women on teratogenic drugs. J Reprod Med 2001;46(Suppl 2):163- 8.
7. Dillman DA. Mail and Internet Surveys. 2nd ed. New York: John Wiley & Sons, Inc., 2000.
8. Lockyer J, Jennet P, Parboosingh J, Maes W. Raising questions in clinical practice. J Contin Educ Health Prof 1988;8:21-6.
9. Motherisk. http://www.motherisk.org/index.jsp (November 15, 2006)
10. Einarson A, Park A, Koren G. How physicians perceive and utilize information from a teratogen information service: The Motherisk Program. BMC Med Educ 2004;4:6 -10.
11. Wells KB, Lewis CE, Leake B, Schleiter MK, Brook RH. The practices of general and subspecialty internists in counselling about smoking and exercise. Am J Public Health 1986;76:1009-13.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.